Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

236.59 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
$1000 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
Via Benzinga
ResMed Chief Administrative Officer and Global General Counsel to Retire
From ResMed Inc.
Via GlobeNewswire
3 Incredible Growth Stocks to Buy Right Now
These mid-cap growth stocks could deliver market-beating returns in 2023 and beyond. 
Via The Motley Fool
$100 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
Via Benzinga
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
From ResMed Inc.
Via GlobeNewswire
$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Hopeful Golden Cross Forms On ResMed's Chart
Via Benzinga
A Preview Of ResMed's Earnings
Via Benzinga
Where ResMed Stands With Analysts
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
From ResMed Inc.
Via GlobeNewswire
Competitor Recall Continues To Show Opportunities For ResMed
Via Benzinga
ResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair Emeritus
From ResMed Inc.
Via GlobeNewswire
ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
Earnings Scheduled For January 26, 2023
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is estimated to report quarterly earnings at $0.14 per share on revenue of $7.20 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
From ResMed Inc.
Via GlobeNewswire
Looking Into ResMed's Return On Capital Employed
According to Benzinga Pro, during Q1, ResMed (NYSE:RMD) earned $210.48 million, a 7.9% increase from the preceding quarter. ResMed also posted a total of $950.29 million in sales, a 3.89% increase... 
Via Benzinga
Company Report Roundup: Tesla, Tractor Supply, American Express, and More
Plus a look at investing books, stocks to watch, and other topics for investors. 
Via The Motley Fool
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023
From ResMed Inc.
Via GlobeNewswire
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
From ResMed Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Silk Road Medical Stock Scores Relative Strength Rating Upgrade
Silk Road Medical sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
Hopeful Golden Cross Forms On ResMed's Chart
If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE:RMD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. 
Via Benzinga
Tuesday Is Your Last Chance To Buy ResMed Before The Dividend Payout
  Tuesday marks the last chance for investors to receive the next dividend payout from ResMed (NYSE:RMD). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.